BNP Paribas Funds Health Care Innovators Classic Capitalisation
Equity fund
1 year
USA
Largest region
Medium
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- The investment objective of the fund is to increase the value of its assets over the medium term by investing in healthcare innovative companies.
Investment horizon
- BNP Paribas Funds Health Care Innovators Classic Capitalisation is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
08 Sept 2025
- Start date16 May 2013
- ISINLU0823416762
Risk
- Medium (4 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Annual cost
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
Other costs
- Performance-based fee
- Transaction costs
Costs for any currency exchanges are not included.
Allocation
- Stocks 99%Interest 1%
Portfolio
Shows the fund's largest investments.
- Eli Lilly and Co9.4%
- AstraZeneca PLC7.7%
- Sanofi SA5.0%
- Boston Scientific Corp4.9%
- Gilead Sciences Inc4.1%
- Intuitive Surgical Inc4.1%
- Thermo Fisher Scientific Inc3.7%
- Vertex Pharmaceuticals Inc3.7%
- Neurocrine Biosciences Inc3.6%
- Jazz Pharmaceuticals PLC3.5%